Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
753.03
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
42
43
Next >
Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish
January 12, 2024
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS)
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) qualifies as a quality stock.
January 12, 2024
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)
Via
Chartmill
Could Regeneron Stock Help You Retire a Millionaire?
January 10, 2024
The blossoming biotech might give more than a nudge to investors in this project.
Via
The Motley Fool
3 health care stocks off to strong starts in 2024
January 10, 2024
With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Beyond The Numbers: 13 Analysts Discuss Regeneron Pharmaceuticals Stock
January 09, 2024
Via
Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today
January 05, 2024
Via
Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals?
December 27, 2023
Via
Benzinga
Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes
January 08, 2024
Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco.
Via
Investor's Business Daily
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
January 07, 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...
Via
Talk Markets
Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024
January 05, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
January 05, 2024
Shares soared and then tumbled Friday after the company offered $275 million in public shares.
Via
Investor's Business Daily
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals
December 22, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 04, 2024
Via
Benzinga
2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)
January 04, 2024
These innovative biotechs likely aren't done rewarding their shareholders.
Via
The Motley Fool
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Records 52-Week High Wednesday Morning
January 03, 2024
Via
Investor Brand Network
2 gene-editing stocks reshaping hereditary disease treatments
January 02, 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal
Via
MarketBeat
Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent
December 28, 2023
Wednesday, a court ruling that found Viatris Inc's (NASDAQ:
Via
Benzinga
Where Will Regeneron Pharmaceuticals Be in 1 Year?
December 22, 2023
Can the stock continue its market-beating ways?
Via
The Motley Fool
14 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know
December 18, 2023
Via
Benzinga
Price Over Earnings Overview: Regeneron Pharmaceuticals
December 18, 2023
Via
Benzinga
Thoughts For Thursday: With War Clouds As A Backdrop The Market Is Set To End The Year On A High
December 28, 2023
The market looks set to end 2023 on a high note, but 2024 is less certain, particularly because though, the US does not want further action in the Gulf, it seems, Iran via its proxies is gaming for...
Via
Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
December 27, 2023
Via
Benzinga
Visualized: The Top S&P 500 Stocks Over 20 Years
December 27, 2023
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
7 Undervalued Nasdaq-100 Stocks for Bargain Hunters
December 21, 2023
Though tech innovators blossomed this year, you can still find undervalued deals.
Via
InvestorPlace
$1000 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
December 21, 2023
Via
Benzinga
Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
December 17, 2023
You can pick these players up for a great price right now.
Via
The Motley Fool
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
December 16, 2023
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
42
43
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.